UFF
CPRX icon

USA Financial Formulas’s Catalyst Pharmaceutical CPRX Stock Holding History

USA Financial Formulas’s Portfolio CPRX Stock Details CPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-1,037
Closed -$21.6K – 298
2024
Q4 		$21.6K Buy
+1,037
New +$22.3K ﹤0.01% 268
2022
Q3 		$239K Buy
+18,644
New +$221K 0.38% 49
2022
Q2 		– Sell
-12,870
Closed -$107K – 352
2022
Q1 		$107K Sell
12,870
-16,101
-56% -$114K 0.11% 84
2021
Q4 		$196K Buy
+28,971
New +$191K 0.17% 89
2019
Q4 		– Sell
-38,169
Closed -$203K – 240
2019
Q3 		$203K Buy
+38,169
New +$203K 0.08% 130

Other funds holding CPRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Fundsmith LLP
Fundsmith LLP London, United Kingdom $12.8B AUM 6.9% 1-Year Est. Return

USA Financial Formulas's CPRX Position: Q1 2025 in Review

USA Financial Formulas sold out of Catalyst Pharmaceutical (CPRX) in Q1 2025, closing a stake of 1,037 shares — an estimated $21.6K sold.

USA Financial Formulas first reported a position in CPRX in Q3 2019 and held it in 5 quarters. The position peaked at $239K in Q3 2022. 371 funds tracked by Wall St. Rank hold CPRX as of Q1 2025.

  • USA Financial Formulas reported no remaining Catalyst Pharmaceutical position as of Q1 2025 after selling out during the quarter.
  • USA Financial Formulas sold 1,037 Catalyst Pharmaceutical shares in Q1 2025, an estimated $21.6K.
  • USA Financial Formulas first reported a position in Catalyst Pharmaceutical in Q3 2019 and held it in 5 quarters.
  • USA Financial Formulas's Catalyst Pharmaceutical position peaked at $239K in Q3 2022.
  • 371 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q1 2025.

Based on USA Financial Formulas's 13F filing for Q1 2025, filed 15 Apr 2025.